НовостиBenzingaVeradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile Benzinga 2026.10.19 11:13 (GMT+0) Открыть на Benzinga Другие новости